FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins

Blood

Volumn 111, Issue 1, 2008, Pages 338-343

  Du, Xing ^a   Nagata, Satoshi ^a   Ise, Tomoko ^a   Stetler Stevenson, Maryalice ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANE PROTEIN; CELL SURFACE PROTEIN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FCRL1; PROTEIN FCRL1; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; RECOMBINANT IMMUNOTOXIN PE38; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CANCER CELL; CELL LINE; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOTHERAPY; MANTLE CELL LYMPHOMA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; TREATMENT PLANNING;

EID: 38049156458     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-102350     Document Type: Article

References (33)

1. Davis RS. Fc receptor-like molecules. Annu Rev Immunol. 2007;25:525-560.
2. Maltais LJ, Lovering RC, Taranin AV, et al. New nomenclature for Fc receptor-like molecules. Nat Immunol. 2006;7:431-432.
3. Ise T, Maeda H, Santora K, et al. Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies. Clin Cancer Res. 2005;11:87-96.
4. Ise T, Nagata S, Kreitman RJ, et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 2007;21:169-174.
5. Polson AG, Zheng B, Elkins K, et al. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol. 2006;18:1363-1373.
6. Falini B, Tiacci E, Pucciarini A, et al. Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). Blood. 2003;102:3684-3692.
7. Zinzani PL, Dirnhofer S, Sabattini E, et al. Identification of outcome predictors in diffuse large B-cell lymphoma: immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue microarrays. Haematologica. 2005;90:341-347.
8. Miller I, Hatzivassiliou G, Cattoretti G, Mendelsohn C, Dalla-Favera R. IRTAs: a new family of immunoglobulinlike receptors differentially expressed in B cells. Blood. 2002;99:2662-2669.
9. Davis RS, Wang YH, Kubagawa H, Cooper MD. Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci U S A. 2001;98:9772-9777.
10. Leu CM, Davis RS, Gartland LA, Fine WD, Cooper MD. FcRH1: an activation coreceptor on human B cells. Blood. 2005;105:1121-1126.
11. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer. 2006;6:559-565.
12. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med. 2007;58:221-237.
13. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000;18:1622-1636.
14. Mansfield E, Amlot P, Pastan I, FitzGerald DJ. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood. 1997;90:2020-2026.
15. Nagata S, Onda M, Numata Y, et al. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res. 2002;8:2345-2355.
16. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother. 2007;30:607-613.
17. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10:3937-3942.
18. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241-247.
19. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005;23:6719-6729.
20. Genbank, NCBI database, http://www.ncbi.nlm.nih.gov/Genbank/index.html. Accessed June 12, 2006.
21. Nagata S, Salvatore G, Pastan I. DNA immunization followed by a single boost with cells: a protein-free immunization protocol for production of monoclonal antibodies against the native form of membrane proteins. J Immunol Methods. 2003;280:59-72.
22. Nagata S, Yamamoto K, Ueno Y, Kurata T, Chiba J. Preferential generation of monoclonal IgG-producing hybridomas by use of vesicular stomatitis virus-mediated cell fusion. Hybridoma. 1991;10:369-378.
23. Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods. 1985;77:305-319.
24. Nagata S, Numata Y, Onda M, et al. Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay. J Immunol Methods. 2004;292:141-155.
25. Ahmad E, Kingma DW, Jaffe ES, et al. Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow. Cytometry B Clin Cytom. 2005;67:6-12.
26. Borowitz MJ, Bray R, Gascoyne R, et al. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. Cytometry. 1997;30:236-244.
27. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol. 2004;248:503-518.
28. Kosmas C, Stamatopoulos K, Papadaki T, et al. Somatic hypermutation of immunoglobulin variable region genes: focus on follicular lymphoma and multiple myeloma. Immunol Rev. 1998;162:281-292.
29. Weng L, Gesk S, Martin-Subero JI, et al. Interphase cytogenetic characterization of aberrations in the long arm of chromosome 1 in B-cell lymphoid malignancies. Cancer Genet Cytogenet. June 12, 2006. 2003;144:83-84.
30. Lestou VS, Ludkovski O, Connors JM, et al. Characterization of the recurrent translocation t(1;1)(p36.3;q21.1-2) in non-Hodgkin lymphoma by multicolor banding and fluorescence in situ hybridization analysis. Genes Chromosom Cancer. 2003;36:375-381.
31. Sobol H, Benziane A, Kerangueven F, et al. Genome-wide search for loss of heterozygosity in Burkitt lymphoma cell lines. Genes Chromosom Cancer. 2002;33:217-224.
32. Hatzivassiliou G, Miller I, Takizawa J, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity. 2001;14:277-289.
33. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018-1028.